New Collaborative Grant Aims to Overcome Immunotherapy Resistance in Melanoma Patients#United_States#New_York#TIL_therapy#Israel_Cancer_Research_Fund#Cancer_Research_Institute
New Collaborative Grant Aims to Overcome Immunotherapy Resistance in Melanoma Patients
The Israel Cancer Research Fund and Cancer Research Institute announce a grant to enhance TIL therapy, helping fight melanoma through personalized treatments.
third-news.com
January 22, 2026 at 2:00 PM
New Collaborative Grant Aims to Overcome Immunotherapy Resistance in Melanoma Patients#United_States#New_York#TIL_therapy#Israel_Cancer_Research_Fund#Cancer_Research_Institute
Exploring the Surge of Tumor-Infiltrating Lymphocyte Therapy in Oncology#None#oncology#TIL_therapy#Tumor-Infiltrating_Lymphocyte
Exploring the Surge of Tumor-Infiltrating Lymphocyte Therapy in Oncology
The Tumor-Infiltrating Lymphocyte (TIL) therapy market is expanding rapidly, driven by breakthrough innovations and promising clinical outcomes in oncology. Discover key trends and projections.
third-news.com
August 12, 2025 at 9:39 PM
Exploring the Surge of Tumor-Infiltrating Lymphocyte Therapy in Oncology#None#oncology#TIL_therapy#Tumor-Infiltrating_Lymphocyte
Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025#China#Shanghai#Juncell_Therapeutics#TIL_therapy#IL-2-Independent
Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025
At the ASGCT Annual Meeting 2025, Juncell Therapeutics will present its breakthroughs in IL-2-independent TIL manufacturing, showcasing promising anti-tumor capabilities.
third-news.com
April 29, 2025 at 12:10 AM
Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025#China#Shanghai#Juncell_Therapeutics#TIL_therapy#IL-2-Independent
Juncell Therapeutics Unveils Promising TIL Therapy Data at AACR 2025#China#Shanghai#Juncell_Therapeutics#TIL_therapy#AACR_2025
Juncell Therapeutics Unveils Promising TIL Therapy Data at AACR 2025
At the AACR Annual Meeting 2025, Juncell Therapeutics presented preclinical data showing innovative pretreatment methods for TIL therapy, highlighting hydroxychloroquine's role.
third-news.com
March 26, 2025 at 1:48 PM
Juncell Therapeutics Unveils Promising TIL Therapy Data at AACR 2025#China#Shanghai#Juncell_Therapeutics#TIL_therapy#AACR_2025
Revolutionary TIL Therapy: A New Hope for Metastatic Melanoma Patients in Washington, D.C.#United_States#Washington#TIL_therapy#Metastatic_Melanoma#MedStar_Georgetown
Revolutionary TIL Therapy: A New Hope for Metastatic Melanoma Patients in Washington, D.C.
MedStar Georgetown University Hospital introduces TIL therapy for metastatic melanoma, marking a significant advancement in cancer treatment options for patients.
third-news.com
January 8, 2025 at 2:24 PM
Revolutionary TIL Therapy: A New Hope for Metastatic Melanoma Patients in Washington, D.C.#United_States#Washington#TIL_therapy#Metastatic_Melanoma#MedStar_Georgetown
Juncell Therapeutics Unveils Cutting-Edge Facility to Advance Cancer Therapy Production#China#Shanghai#Juncell_Therapeutics#TIL_therapy
Juncell Therapeutics Unveils Cutting-Edge Facility to Advance Cancer Therapy Production
Juncell Therapeutics has inaugurated a modern facility in Shanghai to enhance the production of innovative TIL therapies, paving the way for advancements in cancer treatment.
third-news.com
December 18, 2024 at 1:12 PM
Juncell Therapeutics Unveils Cutting-Edge Facility to Advance Cancer Therapy Production#China#Shanghai#Juncell_Therapeutics#TIL_therapy